Supernus PharmaceuticalsSUPN +1.53%87 FCF Margin % is 32.03% as of Mar. 2026, which is 24% above its 10-year median of 25.88. GuruFocus rates SUPN with a GF Score™ of 87/100 and a GF Value™ of $40.55 (Modestly Overvalued). Among 958 Drug Manufacturers companies, Supernus Pharmaceuticals ranks better than 71.82% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (SUPN) has a FCF Margin % of 32.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Supernus Pharmaceuticals and its competitors. This is 24% above median its historical median of 25.88. Over the past decade, Supernus Pharmaceuticals' FCF Margin % has ranged from 6.40 to 37.26. According to the industry distribution chart, Supernus Pharmaceuticals ranks #270 out of 958 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Supernus Pharmaceuticals' FCF Margin % too high?
Supernus Pharmaceuticals' current FCF Margin % of 32.03% is 24% above median its 10-year median of 25.88. Over the past 10 years, this metric has ranged from a low of 6.40 to a high of 37.26. The Drug Manufacturers industry median FCF Margin % is 2.51. Supernus Pharmaceuticals' value of 32.03% is 1176.1% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #270 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' FCF Margin % compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #270 out of 958 companies for FCF Margin %. This puts Supernus Pharmaceuticals in the upper half of its industry. The industry median FCF Margin % is 2.51. Supernus Pharmaceuticals' value of 32.03% is 1176.1% above this benchmark. Historically, Supernus Pharmaceuticals' own FCF Margin % has ranged from 6.40 to 37.26 over the past decade. While the company's 10-year median is 25.88 vs. the industry median of 2.51, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current FCF Margin % of 32.03% is 1176.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current FCF Margin % is 32.03%, which is 24% above median its own 10-year median of 25.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (SUPN) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.55, compared to a current price of $45.13 — trading 11.3% above its estimated fair value. The current FCF Margin % is 32.03%, which is 24% above median its 10-year median of 25.88 and 1176.1% above the Drug Manufacturers industry median of 2.51. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Supernus Pharmaceuticals (SUPN), the current FCF Margin % is 32.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (SUPN) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $45.13 is trading 11.3% above its estimated GF Value™ of $40.55.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for SUPN:
FCF Margin %: 32.03% (24% above median its 10-year median of 25.88)
GF Value™: $40.55 vs. price of $45.13 (11.3% above fair value)
Industry Position: 1176.1% above the Drug Manufacturers median (#270 of 958)
No single metric tells the full story. See the SUPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score
Get the complete analysis for SUPN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUPN has been successfully added to your 
